Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts [Seeking Alpha]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Seeking Alpha
That is not too far away, but that doesn't mean that there aren't any near-term catalysts for investors to focus on. It is expected that initial data from the pediatric phase 1/2 REVEAL study targeting Rett Syndrome will be released in mid-2024, which is going to entail the lower dose of 5.7X10^14 total vg of gene therapy. From there further data from this pediatric study is expected to be released in the 2nd half of 2024. This is going to be with respect to cohort 2, which is using the higher dose of 1X10^15 total vg of TSHA-102. With initial data already released for the Rett Syndrome gene therapy being developed, plus several other catalysts for Taysha Gene Therapies, Inc. on the way, I believe that investors could benefit from any potential gains made. Please subscribe to my Seeking Alpha Marketplace Service " ", whereby you can subscribe to either my "Full Tier" at $399/yr or my "Basic Tier" service at $299/yr instead. If you want to see what my articles are about you could
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.MarketBeat
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
TSHA
Earnings
- 11/14/23 - Miss
TSHA
Sec Filings
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form ARS
- 4/18/24 - Form DEF
- TSHA's page on the SEC website